 Richard Schulick
Concepts (891)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 162 | 2023 | 734 | 17.380 |
Why?
| | Pancreaticoduodenectomy | 59 | 2023 | 128 | 7.500 |
Why?
| | Adenocarcinoma | 68 | 2023 | 812 | 5.960 |
Why?
| | Carcinoma, Pancreatic Ductal | 47 | 2023 | 210 | 5.910 |
Why?
| | Pancreatectomy | 47 | 2023 | 165 | 4.610 |
Why?
| | Liver Neoplasms | 53 | 2020 | 527 | 4.270 |
Why?
| | Hepatectomy | 36 | 2021 | 139 | 2.350 |
Why?
| | Neuroendocrine Tumors | 12 | 2023 | 83 | 2.260 |
Why?
| | Pancreatic Cyst | 12 | 2022 | 47 | 2.070 |
Why?
| | Laparoscopy | 14 | 2022 | 418 | 1.900 |
Why?
| | General Surgery | 7 | 2021 | 138 | 1.840 |
Why?
| | Common Bile Duct Neoplasms | 9 | 2023 | 23 | 1.840 |
Why?
| | Bile Duct Neoplasms | 13 | 2021 | 55 | 1.830 |
Why?
| | Colorectal Neoplasms | 21 | 2014 | 628 | 1.790 |
Why?
| | Pancreas | 16 | 2023 | 282 | 1.590 |
Why?
| | Carcinoma, Neuroendocrine | 8 | 2023 | 31 | 1.570 |
Why?
| | Neoadjuvant Therapy | 22 | 2023 | 333 | 1.550 |
Why?
| | Neoplasm Recurrence, Local | 26 | 2023 | 900 | 1.520 |
Why?
| | Cancer Vaccines | 7 | 2020 | 139 | 1.510 |
Why?
| | Humans | 320 | 2023 | 119032 | 1.490 |
Why?
| | Cholangiocarcinoma | 11 | 2012 | 38 | 1.490 |
Why?
| | Neoplasm Staging | 40 | 2023 | 1223 | 1.480 |
Why?
| | Survival Rate | 52 | 2023 | 1720 | 1.430 |
Why?
| | Bile Ducts, Intrahepatic | 11 | 2012 | 53 | 1.420 |
Why?
| | Postoperative Complications | 28 | 2023 | 2235 | 1.400 |
Why?
| | Stomach Neoplasms | 5 | 2014 | 67 | 1.350 |
Why?
| | Prognosis | 62 | 2023 | 3443 | 1.350 |
Why?
| | Adenocarcinoma, Mucinous | 9 | 2023 | 59 | 1.310 |
Why?
| | Middle Aged | 168 | 2023 | 27627 | 1.300 |
Why?
| | Aged | 154 | 2023 | 19661 | 1.270 |
Why?
| | Retrospective Studies | 97 | 2023 | 12990 | 1.260 |
Why?
| | Carcinoma, Hepatocellular | 11 | 2016 | 227 | 1.180 |
Why?
| | Female | 207 | 2023 | 61588 | 1.090 |
Why?
| | Male | 191 | 2023 | 57818 | 1.060 |
Why?
| | Pancreatic Fistula | 6 | 2022 | 21 | 1.050 |
Why?
| | Ampulla of Vater | 9 | 2023 | 28 | 1.020 |
Why?
| | Biomarkers, Tumor | 19 | 2022 | 1059 | 1.000 |
Why?
| | Robotics | 3 | 2015 | 83 | 0.980 |
Why?
| | Aged, 80 and over | 75 | 2021 | 6562 | 0.980 |
Why?
| | Neoplasms, Second Primary | 4 | 2019 | 93 | 0.950 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2022 | 158 | 0.940 |
Why?
| | Early Detection of Cancer | 6 | 2020 | 360 | 0.910 |
Why?
| | Chemotherapy, Adjuvant | 20 | 2023 | 360 | 0.910 |
Why?
| | Patient Care Team | 7 | 2021 | 522 | 0.900 |
Why?
| | Quality-Adjusted Life Years | 2 | 2013 | 103 | 0.860 |
Why?
| | Pancreatic Ducts | 6 | 2012 | 66 | 0.830 |
Why?
| | Carcinoma | 5 | 2018 | 204 | 0.800 |
Why?
| | Internship and Residency | 4 | 2021 | 1006 | 0.790 |
Why?
| | Portal Vein | 6 | 2021 | 90 | 0.780 |
Why?
| | Faculty, Medical | 2 | 2018 | 252 | 0.760 |
Why?
| | Healthcare Disparities | 5 | 2014 | 496 | 0.760 |
Why?
| | Listeria monocytogenes | 5 | 2012 | 110 | 0.750 |
Why?
| | Tomography, X-Ray Computed | 23 | 2021 | 2436 | 0.720 |
Why?
| | Cost-Benefit Analysis | 2 | 2013 | 554 | 0.720 |
Why?
| | Stents | 5 | 2011 | 457 | 0.720 |
Why?
| | Treatment Outcome | 60 | 2023 | 9346 | 0.710 |
Why?
| | Combined Modality Therapy | 17 | 2023 | 1167 | 0.710 |
Why?
| | Adult | 107 | 2022 | 31525 | 0.700 |
Why?
| | Pancreatic Diseases | 7 | 2019 | 63 | 0.680 |
Why?
| | Colonic Neoplasms | 8 | 2020 | 224 | 0.670 |
Why?
| | Survival Analysis | 27 | 2022 | 1267 | 0.670 |
Why?
| | Follow-Up Studies | 32 | 2021 | 4596 | 0.670 |
Why?
| | Tumor Microenvironment | 9 | 2022 | 454 | 0.670 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 18 | 0.660 |
Why?
| | Proportional Hazards Models | 20 | 2023 | 1125 | 0.660 |
Why?
| | Immunotherapy | 12 | 2022 | 493 | 0.650 |
Why?
| | Lymphatic Metastasis | 22 | 2018 | 307 | 0.630 |
Why?
| | Mentors | 3 | 2021 | 166 | 0.630 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 29 | 0.620 |
Why?
| | Leadership | 2 | 2018 | 311 | 0.610 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2008 | 43 | 0.610 |
Why?
| | Vascular Surgical Procedures | 5 | 2021 | 262 | 0.600 |
Why?
| | Hospitals | 3 | 2019 | 601 | 0.590 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2023 | 1390 | 0.560 |
Why?
| | Adrenalectomy | 2 | 2006 | 79 | 0.560 |
Why?
| | Cholecystectomy | 4 | 2014 | 45 | 0.550 |
Why?
| | Antineoplastic Agents | 11 | 2021 | 1974 | 0.550 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 118 | 0.550 |
Why?
| | Education, Medical, Continuing | 2 | 2015 | 125 | 0.540 |
Why?
| | Carcinoma, Papillary | 6 | 2017 | 76 | 0.540 |
Why?
| | Benchmarking | 3 | 2021 | 172 | 0.520 |
Why?
| | Quality Assurance, Health Care | 2 | 2015 | 325 | 0.510 |
Why?
| | Cholelithiasis | 1 | 2014 | 30 | 0.510 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 250 | 0.500 |
Why?
| | Learning Curve | 1 | 2015 | 67 | 0.500 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 18 | 0.500 |
Why?
| | Biomedical Research | 2 | 2013 | 612 | 0.500 |
Why?
| | Lymphedema | 1 | 2014 | 21 | 0.490 |
Why?
| | Bile Ducts, Extrahepatic | 3 | 2012 | 28 | 0.490 |
Why?
| | Adenoma | 5 | 2020 | 191 | 0.490 |
Why?
| | Cyclophosphamide | 5 | 2020 | 222 | 0.490 |
Why?
| | Mesenteric Veins | 3 | 2021 | 10 | 0.490 |
Why?
| | Pheochromocytoma | 3 | 2013 | 54 | 0.480 |
Why?
| | SEER Program | 11 | 2011 | 205 | 0.480 |
Why?
| | Esophageal Neoplasms | 4 | 2023 | 281 | 0.480 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2013 | 81 | 0.470 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2014 | 118 | 0.470 |
Why?
| | Liver Neoplasms, Experimental | 4 | 2014 | 25 | 0.470 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 93 | 0.470 |
Why?
| | Catheter Ablation | 11 | 2012 | 286 | 0.470 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2220 | 0.470 |
Why?
| | Thrombelastography | 3 | 2020 | 192 | 0.470 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2016 | 176 | 0.460 |
Why?
| | Neoplasm Invasiveness | 20 | 2020 | 462 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 8 | 2021 | 1200 | 0.460 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 359 | 0.460 |
Why?
| | Genetic Predisposition to Disease | 7 | 2018 | 2275 | 0.450 |
Why?
| | Risk Assessment | 19 | 2020 | 3057 | 0.450 |
Why?
| | Nomograms | 3 | 2022 | 48 | 0.450 |
Why?
| | Neoplasms | 9 | 2022 | 2179 | 0.450 |
Why?
| | Rectal Neoplasms | 5 | 2017 | 121 | 0.430 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2009 | 13 | 0.430 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 75 | 0.430 |
Why?
| | Incidental Findings | 7 | 2021 | 80 | 0.420 |
Why?
| | Cystadenoma, Serous | 4 | 2020 | 17 | 0.420 |
Why?
| | Immunohistochemistry | 20 | 2019 | 1691 | 0.410 |
Why?
| | Research Personnel | 1 | 2013 | 158 | 0.410 |
Why?
| | Kaplan-Meier Estimate | 19 | 2018 | 842 | 0.410 |
Why?
| | Palliative Care | 6 | 2012 | 629 | 0.410 |
Why?
| | Diagnosis, Differential | 9 | 2022 | 1384 | 0.410 |
Why?
| | Carcinoma, Islet Cell | 3 | 2006 | 3 | 0.410 |
Why?
| | Interleukin-2 | 4 | 2007 | 417 | 0.410 |
Why?
| | Sigmoid Neoplasms | 1 | 2011 | 3 | 0.400 |
Why?
| | Vascular Neoplasms | 4 | 2020 | 16 | 0.400 |
Why?
| | Fluorouracil | 10 | 2016 | 151 | 0.400 |
Why?
| | Solitary Fibrous Tumors | 1 | 2011 | 3 | 0.400 |
Why?
| | Mice, Inbred BALB C | 12 | 2021 | 1206 | 0.390 |
Why?
| | Cohort Studies | 20 | 2023 | 5117 | 0.390 |
Why?
| | Hepatic Artery | 5 | 2020 | 55 | 0.380 |
Why?
| | Patient Care Planning | 4 | 2018 | 143 | 0.380 |
Why?
| | Gamma Rays | 2 | 2021 | 52 | 0.380 |
Why?
| | United States | 33 | 2023 | 12557 | 0.370 |
Why?
| | Cyst Fluid | 4 | 2022 | 27 | 0.370 |
Why?
| | Positron-Emission Tomography | 7 | 2008 | 298 | 0.370 |
Why?
| | MAP Kinase Kinase 4 | 2 | 2006 | 24 | 0.360 |
Why?
| | Length of Stay | 10 | 2021 | 1031 | 0.360 |
Why?
| | Predictive Value of Tests | 16 | 2018 | 1868 | 0.360 |
Why?
| | Integrin alpha2 | 1 | 2009 | 3 | 0.360 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 200 | 0.360 |
Why?
| | Lymph Node Excision | 3 | 2010 | 158 | 0.360 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2023 | 61 | 0.360 |
Why?
| | Disease-Free Survival | 13 | 2023 | 649 | 0.360 |
Why?
| | Mutation | 11 | 2016 | 3457 | 0.350 |
Why?
| | Cystadenocarcinoma, Mucinous | 3 | 2015 | 13 | 0.350 |
Why?
| | Abdominal Abscess | 2 | 2011 | 27 | 0.350 |
Why?
| | Octreotide | 1 | 2009 | 27 | 0.340 |
Why?
| | Adenoma, Islet Cell | 2 | 2006 | 10 | 0.340 |
Why?
| | Klatskin Tumor | 3 | 2021 | 4 | 0.340 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 1999 | 48 | 0.330 |
Why?
| | Robotic Surgical Procedures | 2 | 2021 | 89 | 0.330 |
Why?
| | Time Factors | 20 | 2021 | 6414 | 0.330 |
Why?
| | Chemoradiotherapy | 6 | 2022 | 200 | 0.330 |
Why?
| | Risk Factors | 30 | 2018 | 9003 | 0.330 |
Why?
| | Internationality | 2 | 2020 | 152 | 0.330 |
Why?
| | Mice | 27 | 2022 | 15528 | 0.330 |
Why?
| | Lymph Nodes | 7 | 2012 | 455 | 0.320 |
Why?
| | Pain, Postoperative | 2 | 2021 | 211 | 0.320 |
Why?
| | Choledochal Cyst | 1 | 2008 | 20 | 0.320 |
Why?
| | Biomarkers | 5 | 2022 | 3590 | 0.320 |
Why?
| | Duodenostomy | 1 | 2007 | 5 | 0.320 |
Why?
| | Jejunostomy | 1 | 2007 | 13 | 0.320 |
Why?
| | Gallbladder Neoplasms | 4 | 2010 | 11 | 0.310 |
Why?
| | Digestive System Surgical Procedures | 3 | 2019 | 91 | 0.310 |
Why?
| | Biliary Tract Surgical Procedures | 3 | 2021 | 27 | 0.300 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2016 | 23 | 0.300 |
Why?
| | Cushing Syndrome | 1 | 2006 | 10 | 0.290 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2017 | 42 | 0.290 |
Why?
| | Hyperamylasemia | 2 | 2022 | 3 | 0.290 |
Why?
| | von Hippel-Lindau Disease | 1 | 2006 | 12 | 0.290 |
Why?
| | Anastomosis, Surgical | 4 | 2015 | 146 | 0.290 |
Why?
| | Esophagectomy | 2 | 2022 | 110 | 0.280 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 89 | 0.280 |
Why?
| | Breast Neoplasms | 2 | 2017 | 1965 | 0.280 |
Why?
| | DNA Helicases | 3 | 2012 | 131 | 0.280 |
Why?
| | Liver | 6 | 2020 | 1816 | 0.280 |
Why?
| | Chemoembolization, Therapeutic | 4 | 2012 | 51 | 0.280 |
Why?
| | Interdisciplinary Communication | 3 | 2021 | 191 | 0.280 |
Why?
| | Radiosurgery | 2 | 2020 | 318 | 0.280 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2006 | 152 | 0.270 |
Why?
| | Peritoneal Neoplasms | 2 | 2020 | 53 | 0.270 |
Why?
| | Carcinoma in Situ | 3 | 2012 | 45 | 0.270 |
Why?
| | Endosonography | 4 | 2018 | 142 | 0.270 |
Why?
| | Pancreatitis | 3 | 2022 | 108 | 0.270 |
Why?
| | Protein Kinase Inhibitors | 3 | 2013 | 811 | 0.270 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2018 | 128 | 0.270 |
Why?
| | Cell Proliferation | 8 | 2021 | 2275 | 0.270 |
Why?
| | Hospital Mortality | 10 | 2020 | 814 | 0.270 |
Why?
| | Precancerous Conditions | 4 | 2011 | 160 | 0.260 |
Why?
| | Membrane Proteins | 4 | 2021 | 1056 | 0.260 |
Why?
| | Arteries | 2 | 2019 | 250 | 0.260 |
Why?
| | Genetic Engineering | 1 | 2006 | 83 | 0.260 |
Why?
| | Publishing | 1 | 2007 | 131 | 0.260 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 144 | 0.260 |
Why?
| | Animals | 36 | 2022 | 33399 | 0.260 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2016 | 9 | 0.250 |
Why?
| | Biliary Tract Neoplasms | 4 | 2006 | 20 | 0.250 |
Why?
| | Smad4 Protein | 4 | 2013 | 37 | 0.250 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 1994 | 130 | 0.250 |
Why?
| | Quality Improvement | 3 | 2023 | 963 | 0.250 |
Why?
| | Baltimore | 5 | 2018 | 42 | 0.250 |
Why?
| | Quality of Life | 6 | 2020 | 2369 | 0.250 |
Why?
| | Tumor Cells, Cultured | 6 | 2021 | 874 | 0.250 |
Why?
| | Gastrectomy | 1 | 2005 | 82 | 0.250 |
Why?
| | Cystadenoma, Mucinous | 2 | 2015 | 12 | 0.240 |
Why?
| | Cell Line, Tumor | 12 | 2021 | 2851 | 0.240 |
Why?
| | Prospective Studies | 21 | 2019 | 6477 | 0.230 |
Why?
| | Reoperation | 6 | 2016 | 557 | 0.230 |
Why?
| | Metastasectomy | 1 | 2023 | 12 | 0.230 |
Why?
| | Immunity | 2 | 2021 | 129 | 0.230 |
Why?
| | Nuclear Proteins | 4 | 2012 | 597 | 0.230 |
Why?
| | Genes, Tumor Suppressor | 5 | 2011 | 77 | 0.220 |
Why?
| | Chi-Square Distribution | 8 | 2015 | 525 | 0.220 |
Why?
| | Splenectomy | 3 | 2020 | 57 | 0.220 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 40 | 0.220 |
Why?
| | Proto-Oncogene Proteins | 6 | 2012 | 618 | 0.220 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1774 | 0.220 |
Why?
| | Benzamides | 3 | 2008 | 176 | 0.220 |
Why?
| | Patient Safety | 3 | 2021 | 281 | 0.220 |
Why?
| | Ephrin-B2 | 2 | 2021 | 42 | 0.220 |
Why?
| | Radiotherapy, Adjuvant | 9 | 2016 | 189 | 0.220 |
Why?
| | Immunologic Factors | 2 | 2018 | 225 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 189 | 0.210 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 2 | 2012 | 8 | 0.210 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.210 |
Why?
| | Multivariate Analysis | 9 | 2016 | 1474 | 0.210 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 22 | 0.210 |
Why?
| | Lymphocytes | 2 | 2020 | 347 | 0.210 |
Why?
| | Incidence | 7 | 2019 | 2424 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3175 | 0.210 |
Why?
| | Carcinoembryonic Antigen | 5 | 2015 | 36 | 0.210 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 40 | 0.210 |
Why?
| | Fibrosis | 3 | 2021 | 483 | 0.200 |
Why?
| | Sarcoma | 2 | 2016 | 137 | 0.200 |
Why?
| | Paternalism | 1 | 2021 | 4 | 0.200 |
Why?
| | Quinazolines | 3 | 2013 | 245 | 0.200 |
Why?
| | Disease Progression | 8 | 2022 | 2490 | 0.200 |
Why?
| | Feasibility Studies | 5 | 2020 | 749 | 0.200 |
Why?
| | Employment | 1 | 2022 | 135 | 0.200 |
Why?
| | Melanoma | 2 | 2022 | 664 | 0.200 |
Why?
| | Referral and Consultation | 3 | 2021 | 648 | 0.200 |
Why?
| | Hospitals, Teaching | 3 | 2018 | 104 | 0.200 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 39 | 0.200 |
Why?
| | Gastroenterology | 1 | 2023 | 158 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.190 |
Why?
| | Liver Transplantation | 5 | 2012 | 847 | 0.190 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2020 | 69 | 0.190 |
Why?
| | Recombinant Proteins | 2 | 2006 | 1308 | 0.190 |
Why?
| | Communication | 2 | 2021 | 761 | 0.190 |
Why?
| | Serotonin | 3 | 2012 | 309 | 0.190 |
Why?
| | Oxycodone | 1 | 2021 | 45 | 0.190 |
Why?
| | Tattooing | 2 | 2010 | 10 | 0.190 |
Why?
| | Access to Information | 1 | 2021 | 53 | 0.190 |
Why?
| | Burns, Electric | 1 | 2020 | 20 | 0.190 |
Why?
| | Checklist | 1 | 2021 | 81 | 0.190 |
Why?
| | Tumor Burden | 6 | 2022 | 275 | 0.190 |
Why?
| | Comprehension | 1 | 2022 | 163 | 0.190 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 76 | 0.190 |
Why?
| | Pancreaticojejunostomy | 1 | 2020 | 5 | 0.190 |
Why?
| | Operating Rooms | 1 | 2021 | 90 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 159 | 0.190 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 100 | 0.190 |
Why?
| | Killer Cells, Natural | 2 | 2017 | 381 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2023 | 165 | 0.180 |
Why?
| | Sarcopenia | 2 | 2012 | 72 | 0.180 |
Why?
| | Mice, Inbred C57BL | 8 | 2021 | 4914 | 0.180 |
Why?
| | Algorithms | 2 | 2019 | 1543 | 0.180 |
Why?
| | Faculty | 1 | 2021 | 135 | 0.180 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 57 | 0.180 |
Why?
| | Adolescent | 21 | 2022 | 18483 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2021 | 740 | 0.180 |
Why?
| | Health Literacy | 1 | 2022 | 169 | 0.180 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 49 | 0.180 |
Why?
| | Radiation Injuries | 1 | 2021 | 131 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2012 | 394 | 0.180 |
Why?
| | Preoperative Care | 9 | 2018 | 332 | 0.180 |
Why?
| | Genetic Testing | 3 | 2018 | 389 | 0.180 |
Why?
| | Statistics, Nonparametric | 6 | 2011 | 403 | 0.180 |
Why?
| | Kidney Transplantation | 3 | 1997 | 585 | 0.180 |
Why?
| | Age Factors | 9 | 2022 | 2995 | 0.170 |
Why?
| | Patient-Centered Care | 2 | 2022 | 497 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 176 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 168 | 0.170 |
Why?
| | Adrenocortical Carcinoma | 1 | 1999 | 47 | 0.170 |
Why?
| | Career Choice | 2 | 2018 | 192 | 0.170 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 29 | 0.170 |
Why?
| | Safety Management | 2 | 2010 | 109 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2021 | 248 | 0.170 |
Why?
| | Neoplasm Proteins | 3 | 2008 | 401 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 156 | 0.170 |
Why?
| | ras Proteins | 4 | 2012 | 141 | 0.170 |
Why?
| | Thalidomide | 1 | 2018 | 28 | 0.170 |
Why?
| | Flow Cytometry | 5 | 2019 | 1085 | 0.160 |
Why?
| | Analysis of Variance | 8 | 2013 | 1295 | 0.160 |
Why?
| | Europe | 4 | 2021 | 356 | 0.160 |
Why?
| | Radiology | 1 | 2021 | 199 | 0.160 |
Why?
| | Health Resources | 1 | 2019 | 132 | 0.160 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 356 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 199 | 0.160 |
Why?
| | Sentinel Surveillance | 1 | 2018 | 39 | 0.160 |
Why?
| | Job Satisfaction | 2 | 2018 | 175 | 0.160 |
Why?
| | Immunomodulation | 1 | 2018 | 89 | 0.160 |
Why?
| | Thrombophilia | 1 | 2018 | 68 | 0.160 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 64 | 0.160 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 75 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 3 | 2018 | 396 | 0.150 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2019 | 116 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1994 | 985 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 537 | 0.150 |
Why?
| | Telomere | 2 | 2012 | 204 | 0.150 |
Why?
| | Neutrophils | 3 | 2019 | 1233 | 0.150 |
Why?
| | DNA Mutational Analysis | 4 | 2016 | 381 | 0.150 |
Why?
| | Trastuzumab | 1 | 2017 | 92 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2015 | 197 | 0.150 |
Why?
| | Maryland | 4 | 2013 | 36 | 0.150 |
Why?
| | Societies, Medical | 2 | 2018 | 703 | 0.150 |
Why?
| | DNA Mismatch Repair | 1 | 2016 | 28 | 0.150 |
Why?
| | Young Adult | 16 | 2022 | 10799 | 0.150 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 42 | 0.140 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 7 | 0.140 |
Why?
| | Students, Medical | 1 | 2021 | 311 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 35 | 0.140 |
Why?
| | Neoplasm Metastasis | 5 | 2012 | 544 | 0.140 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 31 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2020 | 316 | 0.140 |
Why?
| | Ki-67 Antigen | 2 | 2013 | 108 | 0.140 |
Why?
| | Deoxycytidine | 5 | 2017 | 136 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2018 | 204 | 0.140 |
Why?
| | Cannabis | 1 | 2023 | 382 | 0.140 |
Why?
| | Caregivers | 1 | 2022 | 709 | 0.140 |
Why?
| | Receptors, Immunologic | 1 | 2017 | 209 | 0.140 |
Why?
| | Radiotherapy | 2 | 2019 | 187 | 0.140 |
Why?
| | Neoplasm Grading | 5 | 2016 | 258 | 0.140 |
Why?
| | Viscera | 1 | 2015 | 16 | 0.140 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 24 | 0.140 |
Why?
| | Constriction, Pathologic | 4 | 2011 | 204 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2016 | 59 | 0.140 |
Why?
| | Efficiency | 1 | 2016 | 89 | 0.140 |
Why?
| | Hepatitis | 2 | 2006 | 46 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2008 | 407 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1167 | 0.130 |
Why?
| | Decision Making | 2 | 2012 | 809 | 0.130 |
Why?
| | Logistic Models | 5 | 2016 | 1901 | 0.130 |
Why?
| | Signal Transduction | 8 | 2022 | 4713 | 0.130 |
Why?
| | Cholestasis | 3 | 2011 | 228 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 499 | 0.130 |
Why?
| | Piperazines | 2 | 2008 | 316 | 0.130 |
Why?
| | MicroRNAs | 2 | 2012 | 637 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 367 | 0.130 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 793 | 0.130 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2010 | 83 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Leucovorin | 1 | 2014 | 43 | 0.130 |
Why?
| | Perioperative Period | 2 | 2011 | 51 | 0.130 |
Why?
| | Vitamin B Complex | 1 | 2014 | 37 | 0.120 |
Why?
| | Capecitabine | 4 | 2017 | 46 | 0.120 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 237 | 0.120 |
Why?
| | Pyrimidines | 2 | 2008 | 382 | 0.120 |
Why?
| | Spleen | 1 | 2016 | 510 | 0.120 |
Why?
| | Metabolomics | 1 | 2019 | 550 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 762 | 0.120 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 47 | 0.120 |
Why?
| | Genome | 2 | 2016 | 278 | 0.120 |
Why?
| | Immunoglobulins | 1 | 2014 | 154 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2021 | 830 | 0.120 |
Why?
| | Mitotic Index | 1 | 2013 | 27 | 0.120 |
Why?
| | Colectomy | 2 | 2012 | 84 | 0.120 |
Why?
| | Acinar Cells | 1 | 2013 | 13 | 0.120 |
Why?
| | Pancreas, Exocrine | 1 | 2013 | 8 | 0.120 |
Why?
| | Cystadenoma | 1 | 2013 | 4 | 0.120 |
Why?
| | Exome | 2 | 2011 | 220 | 0.120 |
Why?
| | Cooperative Behavior | 1 | 2016 | 408 | 0.120 |
Why?
| | Survivors | 2 | 2015 | 418 | 0.120 |
Why?
| | Graft Rejection | 2 | 1994 | 555 | 0.120 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 4709 | 0.120 |
Why?
| | Immunosuppressive Agents | 2 | 1997 | 683 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2015 | 147 | 0.110 |
Why?
| | Isoantigens | 1 | 1993 | 19 | 0.110 |
Why?
| | Enzyme Precursors | 1 | 2013 | 15 | 0.110 |
Why?
| | Interpersonal Relations | 1 | 2016 | 345 | 0.110 |
Why?
| | Cell Movement | 3 | 2022 | 897 | 0.110 |
Why?
| | DNA Methylation | 4 | 2008 | 503 | 0.110 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 175 | 0.110 |
Why?
| | Databases, Factual | 6 | 2016 | 1231 | 0.110 |
Why?
| | Protein C | 1 | 2013 | 44 | 0.110 |
Why?
| | Cholangiography | 3 | 2007 | 20 | 0.110 |
Why?
| | Psoas Muscles | 1 | 2012 | 6 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 2 | 2011 | 289 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2008 | 131 | 0.110 |
Why?
| | Japan | 2 | 2023 | 97 | 0.110 |
Why?
| | Tissue Array Analysis | 5 | 2011 | 52 | 0.110 |
Why?
| | Safety | 1 | 2014 | 304 | 0.110 |
Why?
| | Biliopancreatic Diversion | 1 | 2012 | 1 | 0.110 |
Why?
| | Hemangioma | 1 | 2012 | 41 | 0.110 |
Why?
| | Mice, Nude | 5 | 2020 | 663 | 0.110 |
Why?
| | Carcinoma, Large Cell | 1 | 2012 | 14 | 0.110 |
Why?
| | Metoclopramide | 1 | 2012 | 17 | 0.110 |
Why?
| | Ataxia Telangiectasia | 1 | 2011 | 17 | 0.110 |
Why?
| | Interferon-gamma | 4 | 2011 | 737 | 0.110 |
Why?
| | Papilloma, Intraductal | 1 | 2011 | 3 | 0.110 |
Why?
| | Radiopharmaceuticals | 3 | 2008 | 194 | 0.110 |
Why?
| | Glycolipids | 1 | 2012 | 37 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 26 | 0.100 |
Why?
| | Loss of Heterozygosity | 1 | 2012 | 40 | 0.100 |
Why?
| | Liver Cirrhosis | 3 | 2008 | 245 | 0.100 |
Why?
| | Biopsy, Needle | 3 | 2011 | 190 | 0.100 |
Why?
| | Silk | 1 | 2011 | 5 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 417 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2006 | 1175 | 0.100 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2011 | 7 | 0.100 |
Why?
| | Radiography | 5 | 2016 | 861 | 0.100 |
Why?
| | Hyalin | 1 | 2011 | 5 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2012 | 53 | 0.100 |
Why?
| | X Chromosome Inactivation | 2 | 2013 | 21 | 0.100 |
Why?
| | Injections, Intra-Arterial | 1 | 2011 | 25 | 0.100 |
Why?
| | Hepatic Duct, Common | 1 | 2011 | 6 | 0.100 |
Why?
| | Odds Ratio | 5 | 2016 | 996 | 0.100 |
Why?
| | Cysts | 1 | 2012 | 93 | 0.100 |
Why?
| | Comorbidity | 5 | 2022 | 1527 | 0.100 |
Why?
| | Gentamicins | 1 | 2011 | 42 | 0.100 |
Why?
| | Carcinoma, Small Cell | 1 | 2012 | 158 | 0.100 |
Why?
| | Carcinoid Tumor | 1 | 2011 | 25 | 0.100 |
Why?
| | Point Mutation | 1 | 2012 | 228 | 0.100 |
Why?
| | Sutures | 1 | 2011 | 61 | 0.100 |
Why?
| | Ovarian Neoplasms | 2 | 2007 | 420 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2013 | 219 | 0.100 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 202 | 0.100 |
Why?
| | Choice Behavior | 1 | 2012 | 160 | 0.100 |
Why?
| | Transcriptome | 1 | 2016 | 756 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2020 | 245 | 0.100 |
Why?
| | Axons | 1 | 2012 | 185 | 0.100 |
Why?
| | Registries | 4 | 2012 | 1810 | 0.100 |
Why?
| | Drainage | 2 | 2008 | 158 | 0.100 |
Why?
| | Asia | 2 | 2021 | 54 | 0.100 |
Why?
| | Patient Selection | 3 | 2011 | 675 | 0.100 |
Why?
| | Gene Expression | 3 | 2019 | 1492 | 0.090 |
Why?
| | Panniculitis, Peritoneal | 1 | 2010 | 1 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1440 | 0.090 |
Why?
| | Antigens | 1 | 2012 | 320 | 0.090 |
Why?
| | Surgery Department, Hospital | 1 | 2010 | 21 | 0.090 |
Why?
| | Genital Neoplasms, Female | 1 | 2011 | 72 | 0.090 |
Why?
| | Embolization, Therapeutic | 1 | 2012 | 192 | 0.090 |
Why?
| | Antigens, Neoplasm | 1 | 2011 | 228 | 0.090 |
Why?
| | Liver Function Tests | 2 | 2007 | 107 | 0.090 |
Why?
| | Mesentery | 1 | 2010 | 56 | 0.090 |
Why?
| | Cadherins | 1 | 2011 | 186 | 0.090 |
Why?
| | Internal-External Control | 1 | 2010 | 68 | 0.090 |
Why?
| | Sex Factors | 4 | 2022 | 1781 | 0.090 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2009 | 10 | 0.090 |
Why?
| | Morbidity | 4 | 2012 | 296 | 0.090 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2009 | 28 | 0.090 |
Why?
| | Collagen Type IV | 1 | 2009 | 22 | 0.090 |
Why?
| | Uncertainty | 1 | 2010 | 101 | 0.090 |
Why?
| | Drug Synergism | 3 | 2007 | 339 | 0.090 |
Why?
| | Adenoma, Liver Cell | 1 | 2009 | 1 | 0.090 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2006 | 13 | 0.090 |
Why?
| | Biofilms | 1 | 2011 | 231 | 0.090 |
Why?
| | Hospitals, University | 2 | 2010 | 172 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 294 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2008 | 290 | 0.080 |
Why?
| | Chyle | 1 | 2008 | 3 | 0.080 |
Why?
| | CA-19-9 Antigen | 3 | 2022 | 14 | 0.080 |
Why?
| | Chylous Ascites | 1 | 2008 | 6 | 0.080 |
Why?
| | Medical Records | 1 | 2009 | 163 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 1244 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2016 | 2674 | 0.080 |
Why?
| | Academic Medical Centers | 2 | 2012 | 422 | 0.080 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 158 | 0.080 |
Why?
| | Hepatitis, Viral, Human | 1 | 2008 | 26 | 0.080 |
Why?
| | Suture Techniques | 1 | 2009 | 134 | 0.080 |
Why?
| | Genetic Therapy | 1 | 2010 | 267 | 0.080 |
Why?
| | Annexins | 1 | 2008 | 3 | 0.080 |
Why?
| | Laparotomy | 1 | 2008 | 106 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 394 | 0.080 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 112 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 369 | 0.080 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2007 | 5 | 0.080 |
Why?
| | Erlotinib Hydrochloride | 3 | 2013 | 66 | 0.080 |
Why?
| | Gastroscopy | 1 | 2007 | 17 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 394 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 565 | 0.080 |
Why?
| | Antibodies | 2 | 2009 | 392 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1346 | 0.080 |
Why?
| | Gastric Emptying | 1 | 2007 | 40 | 0.080 |
Why?
| | Models, Statistical | 1 | 2011 | 636 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2013 | 963 | 0.080 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 18 | 0.080 |
Why?
| | Histiocytosis, Sinus | 1 | 2007 | 7 | 0.080 |
Why?
| | Anus Neoplasms | 1 | 2007 | 24 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2022 | 2680 | 0.080 |
Why?
| | Blood Urea Nitrogen | 1 | 2007 | 59 | 0.080 |
Why?
| | Electrocoagulation | 1 | 2007 | 36 | 0.080 |
Why?
| | Transaminases | 1 | 2007 | 26 | 0.070 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 114 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 87 | 0.070 |
Why?
| | HIV-1 | 1 | 1993 | 776 | 0.070 |
Why?
| | Pyrroles | 1 | 2008 | 191 | 0.070 |
Why?
| | Hormones, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2007 | 44 | 0.070 |
Why?
| | Receptors, Somatostatin | 1 | 2006 | 25 | 0.070 |
Why?
| | International Agencies | 3 | 2011 | 29 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1597 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3730 | 0.070 |
Why?
| | Operative Time | 2 | 2017 | 114 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 265 | 0.070 |
Why?
| | Somatostatin | 1 | 2006 | 53 | 0.070 |
Why?
| | Thymidylate Synthase | 1 | 2006 | 11 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 168 | 0.070 |
Why?
| | Adrenal Cortex | 1 | 2006 | 34 | 0.070 |
Why?
| | Albumins | 1 | 2007 | 100 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 702 | 0.070 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 146 | 0.070 |
Why?
| | Patient Readmission | 1 | 2012 | 633 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1067 | 0.070 |
Why?
| | Exonucleases | 1 | 2006 | 8 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2013 | 1753 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2009 | 442 | 0.070 |
Why?
| | Pilot Projects | 3 | 2023 | 1420 | 0.070 |
Why?
| | Organizational Culture | 2 | 2021 | 121 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2006 | 446 | 0.070 |
Why?
| | Indoles | 1 | 2008 | 316 | 0.070 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 277 | 0.070 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 33 | 0.070 |
Why?
| | Proteomics | 2 | 2008 | 876 | 0.070 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2007 | 200 | 0.070 |
Why?
| | Paraganglioma | 1 | 2006 | 48 | 0.070 |
Why?
| | Apoptosis | 4 | 2021 | 2484 | 0.070 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 52 | 0.070 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2006 | 140 | 0.070 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 174 | 0.060 |
Why?
| | B7-1 Antigen | 1 | 2005 | 69 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2008 | 569 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 242 | 0.060 |
Why?
| | Hospital Costs | 1 | 2005 | 110 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 308 | 0.060 |
Why?
| | Proteome | 1 | 2008 | 353 | 0.060 |
Why?
| | Postoperative Period | 2 | 2020 | 309 | 0.060 |
Why?
| | Galectin 3 | 1 | 2004 | 20 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2018 | 3173 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 539 | 0.060 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1012 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 133 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2007 | 191 | 0.060 |
Why?
| | Celiac Artery | 2 | 2020 | 9 | 0.060 |
Why?
| | Neuropilin-1 | 1 | 2004 | 9 | 0.060 |
Why?
| | Canada | 2 | 2018 | 340 | 0.060 |
Why?
| | Camptothecin | 1 | 2004 | 100 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 4 | 1985 | 111 | 0.060 |
Why?
| | Mesenteric Artery, Superior | 2 | 2020 | 12 | 0.060 |
Why?
| | Probability | 1 | 2005 | 305 | 0.060 |
Why?
| | Age Distribution | 1 | 2005 | 362 | 0.060 |
Why?
| | Child | 6 | 2009 | 19137 | 0.060 |
Why?
| | Sex Distribution | 1 | 2005 | 351 | 0.060 |
Why?
| | Mass Screening | 2 | 2010 | 1052 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 1 | 2006 | 191 | 0.060 |
Why?
| | Protein Array Analysis | 1 | 2004 | 63 | 0.060 |
Why?
| | Pyridines | 1 | 2007 | 440 | 0.060 |
Why?
| | Cholecystitis | 1 | 2003 | 17 | 0.060 |
Why?
| | Genomic Instability | 1 | 2003 | 38 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 49 | 0.060 |
Why?
| | Pandemics | 2 | 2023 | 1355 | 0.060 |
Why?
| | Cell Communication | 1 | 2005 | 281 | 0.060 |
Why?
| | Transcription Factors | 1 | 2011 | 1570 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2003 | 143 | 0.060 |
Why?
| | Reproducibility of Results | 4 | 2014 | 2874 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 334 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 143 | 0.060 |
Why?
| | Postoperative Hemorrhage | 1 | 2023 | 79 | 0.060 |
Why?
| | Propylamines | 1 | 2022 | 12 | 0.050 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 495 | 0.050 |
Why?
| | Biopsy | 3 | 2013 | 1079 | 0.050 |
Why?
| | Chromogranins | 2 | 2012 | 13 | 0.050 |
Why?
| | Health Care Costs | 1 | 2005 | 394 | 0.050 |
Why?
| | MutL Protein Homolog 1 | 2 | 2016 | 10 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 471 | 0.050 |
Why?
| | X-linked Nuclear Protein | 2 | 2012 | 7 | 0.050 |
Why?
| | Prevalence | 2 | 2023 | 2326 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 253 | 0.050 |
Why?
| | Radiotherapy, Conformal | 2 | 2012 | 67 | 0.050 |
Why?
| | Co-Repressor Proteins | 2 | 2012 | 17 | 0.050 |
Why?
| | Jaundice | 2 | 2011 | 15 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 610 | 0.050 |
Why?
| | Smoking | 1 | 2009 | 1487 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 76 | 0.050 |
Why?
| | Neuropeptides | 1 | 2021 | 68 | 0.050 |
Why?
| | Chemokines | 1 | 2022 | 230 | 0.050 |
Why?
| | Clone Cells | 2 | 2012 | 248 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 182 | 0.050 |
Why?
| | Phenotype | 3 | 2015 | 3004 | 0.050 |
Why?
| | Arginase | 1 | 2020 | 29 | 0.050 |
Why?
| | Pedigree | 2 | 2012 | 485 | 0.050 |
Why?
| | Contrast Media | 3 | 2010 | 373 | 0.050 |
Why?
| | Chromatin Assembly and Disassembly | 2 | 2011 | 93 | 0.050 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1795 | 0.050 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2000 | 9 | 0.050 |
Why?
| | Molecular Chaperones | 2 | 2012 | 174 | 0.050 |
Why?
| | Portal System | 1 | 2020 | 15 | 0.050 |
Why?
| | Terminology as Topic | 2 | 2013 | 211 | 0.050 |
Why?
| | Schools, Medical | 1 | 2021 | 139 | 0.050 |
Why?
| | Platelet Count | 1 | 2020 | 83 | 0.050 |
Why?
| | Mitochondria | 1 | 2006 | 786 | 0.050 |
Why?
| | Educational Status | 1 | 2022 | 437 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 76 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 66 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 455 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2020 | 168 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 567 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 67 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 305 | 0.040 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2012 | 56 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 941 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 625 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2513 | 0.040 |
Why?
| | Abdominal Pain | 2 | 2011 | 134 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 357 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 246 | 0.040 |
Why?
| | Drug Utilization Review | 1 | 2019 | 60 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 128 | 0.040 |
Why?
| | Antigens, Differentiation | 2 | 2011 | 79 | 0.040 |
Why?
| | HIV Infections | 1 | 1993 | 2461 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1988 | 19 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 311 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 755 | 0.040 |
Why?
| | Inflammation | 2 | 2006 | 2571 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 827 | 0.040 |
Why?
| | Ketoconazole | 1 | 1997 | 4 | 0.040 |
Why?
| | Organizational Innovation | 2 | 2010 | 138 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 311 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 1900 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2013 | 2661 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 534 | 0.040 |
Why?
| | Immunocompetence | 1 | 1997 | 43 | 0.040 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 295 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 527 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 306 | 0.040 |
Why?
| | Sclerosis | 2 | 2010 | 14 | 0.040 |
Why?
| | Up-Regulation | 3 | 2007 | 872 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2019 | 262 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
| | Protein Binding | 2 | 2022 | 1975 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2017 | 111 | 0.040 |
Why?
| | Cyclosporine | 1 | 1997 | 173 | 0.040 |
Why?
| | Clinical Audit | 1 | 2016 | 13 | 0.040 |
Why?
| | MutS Homolog 2 Protein | 1 | 2016 | 14 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 513 | 0.040 |
Why?
| | Obesity | 1 | 2010 | 2751 | 0.040 |
Why?
| | Program Evaluation | 1 | 2021 | 845 | 0.040 |
Why?
| | Patient Satisfaction | 2 | 2012 | 610 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 132 | 0.040 |
Why?
| | Ultrasonography | 2 | 2011 | 716 | 0.040 |
Why?
| | Microsomes, Liver | 3 | 1985 | 59 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2021 | 489 | 0.040 |
Why?
| | Adenosine | 2 | 1988 | 211 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 39 | 0.040 |
Why?
| | Metaplasia | 2 | 2006 | 57 | 0.040 |
Why?
| | Giant Cells | 1 | 2016 | 22 | 0.040 |
Why?
| | Immunoenzyme Techniques | 2 | 2014 | 195 | 0.040 |
Why?
| | Margins of Excision | 1 | 2016 | 31 | 0.030 |
Why?
| | Pain Management | 1 | 2019 | 293 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 681 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 732 | 0.030 |
Why?
| | Machine Learning | 1 | 2019 | 331 | 0.030 |
Why?
| | Gadolinium DTPA | 2 | 2006 | 54 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 55 | 0.030 |
Why?
| | HCT116 Cells | 2 | 2006 | 68 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 984 | 0.030 |
Why?
| | Infection Control | 1 | 2016 | 135 | 0.030 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 56 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2008 | 828 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2873 | 0.030 |
Why?
| | Carbon Tetrachloride | 2 | 1985 | 9 | 0.030 |
Why?
| | Vascular Patency | 1 | 2015 | 98 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 111 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2016 | 204 | 0.030 |
Why?
| | Patient Transfer | 1 | 2016 | 143 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 954 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 910 | 0.030 |
Why?
| | Weight Loss | 2 | 2011 | 658 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2006 | 190 | 0.030 |
Why?
| | Phosgene | 2 | 1984 | 6 | 0.030 |
Why?
| | Medical Oncology | 1 | 2016 | 229 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 290 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 473 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2013 | 26 | 0.030 |
Why?
| | Chromosomes, Human, X | 1 | 2013 | 58 | 0.030 |
Why?
| | Immunologic Techniques | 1 | 1993 | 40 | 0.030 |
Why?
| | Proteins | 2 | 2012 | 938 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 890 | 0.030 |
Why?
| | Diabetes Mellitus | 2 | 2012 | 945 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2012 | 1 | 0.030 |
Why?
| | Influenza A virus | 1 | 1993 | 91 | 0.030 |
Why?
| | Heredity | 1 | 2012 | 11 | 0.030 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2012 | 16 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2011 | 11 | 0.030 |
Why?
| | Review Literature as Topic | 1 | 2012 | 68 | 0.030 |
Why?
| | HIV Seropositivity | 1 | 1993 | 111 | 0.030 |
Why?
| | Laser Capture Microdissection | 1 | 2012 | 26 | 0.030 |
Why?
| | Gene Dosage | 1 | 2012 | 136 | 0.030 |
Why?
| | Codon | 1 | 2012 | 89 | 0.030 |
Why?
| | Xanthines | 2 | 1988 | 15 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 120 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 62 | 0.030 |
Why?
| | Periodic Acid-Schiff Reaction | 1 | 2011 | 3 | 0.030 |
Why?
| | China | 1 | 2012 | 175 | 0.030 |
Why?
| | Cytodiagnosis | 1 | 2011 | 27 | 0.030 |
Why?
| | Oncogene Proteins | 1 | 2011 | 52 | 0.030 |
Why?
| | Mitosis | 1 | 2012 | 172 | 0.030 |
Why?
| | Ablation Techniques | 1 | 2011 | 29 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2011 | 136 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2012 | 162 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 81 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1993 | 334 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 564 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 86 | 0.020 |
Why?
| | Frozen Sections | 1 | 2011 | 24 | 0.020 |
Why?
| | Minnesota | 1 | 2011 | 137 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 287 | 0.020 |
Why?
| | Neprilysin | 1 | 2011 | 48 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 627 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 129 | 0.020 |
Why?
| | Gene Frequency | 1 | 2012 | 513 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1993 | 313 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 341 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 80 | 0.020 |
Why?
| | Carcinoma, Ductal | 1 | 2010 | 12 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 2010 | 23 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2011 | 148 | 0.020 |
Why?
| | Portugal | 1 | 2010 | 9 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3666 | 0.020 |
Why?
| | Personnel Turnover | 1 | 2010 | 27 | 0.020 |
Why?
| | Organizational Case Studies | 1 | 2010 | 74 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 364 | 0.020 |
Why?
| | Genes, p16 | 1 | 2010 | 18 | 0.020 |
Why?
| | Gastric Bypass | 1 | 2011 | 93 | 0.020 |
Why?
| | Fanconi Anemia | 1 | 2010 | 12 | 0.020 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2010 | 9 | 0.020 |
Why?
| | Genes, BRCA2 | 1 | 2010 | 25 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 155 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2010 | 51 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2011 | 143 | 0.020 |
Why?
| | Attitude to Death | 1 | 2010 | 61 | 0.020 |
Why?
| | Forms and Records Control | 1 | 2009 | 23 | 0.020 |
Why?
| | Professional Practice | 1 | 2009 | 62 | 0.020 |
Why?
| | beta Catenin | 1 | 2011 | 219 | 0.020 |
Why?
| | Diagnosis-Related Groups | 1 | 2009 | 30 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2010 | 154 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 53 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2009 | 18 | 0.020 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 72 | 0.020 |
Why?
| | Tamoxifen | 1 | 2010 | 198 | 0.020 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2012 | 244 | 0.020 |
Why?
| | Genes, p53 | 1 | 2009 | 64 | 0.020 |
Why?
| | Genes, ras | 1 | 2009 | 95 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 134 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2010 | 321 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2003 | 1158 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 343 | 0.020 |
Why?
| | Postoperative Care | 1 | 2010 | 237 | 0.020 |
Why?
| | Family Health | 1 | 2009 | 201 | 0.020 |
Why?
| | Molecular Probes | 1 | 2008 | 30 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 309 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 2010 | 123 | 0.020 |
Why?
| | Anticoagulants | 1 | 2013 | 559 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 580 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2011 | 452 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2011 | 251 | 0.020 |
Why?
| | Claudins | 1 | 2008 | 24 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 77 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 371 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 1785 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2160 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 975 | 0.020 |
Why?
| | Disease Management | 1 | 2012 | 571 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 361 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 324 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 71 | 0.020 |
Why?
| | Chronic Disease | 2 | 2003 | 1637 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 103 | 0.020 |
Why?
| | Population Surveillance | 1 | 2010 | 413 | 0.020 |
Why?
| | Cell Line | 1 | 1993 | 2707 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 315 | 0.020 |
Why?
| | Evidence-Based Practice | 1 | 2009 | 193 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4196 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 102 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2009 | 210 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1882 | 0.020 |
Why?
| | Tetrahydrofolates | 1 | 2006 | 11 | 0.020 |
Why?
| | Folic Acid Antagonists | 1 | 2006 | 8 | 0.020 |
Why?
| | Medicare | 1 | 2012 | 665 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2008 | 208 | 0.020 |
Why?
| | Gallbladder | 1 | 2006 | 15 | 0.020 |
Why?
| | Macrophages | 1 | 2013 | 1324 | 0.020 |
Why?
| | Lymphotoxin beta Receptor | 1 | 2006 | 2 | 0.020 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2006 | 3 | 0.020 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2006 | 5 | 0.020 |
Why?
| | Concanavalin A | 1 | 2006 | 74 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 410 | 0.020 |
Why?
| | Antigens, Ly | 1 | 2006 | 45 | 0.020 |
Why?
| | Claudin-4 | 1 | 2006 | 9 | 0.020 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 13 | 0.020 |
Why?
| | Lectins, C-Type | 1 | 2006 | 63 | 0.020 |
Why?
| | Halothane | 1 | 1985 | 5 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 523 | 0.020 |
Why?
| | Overweight | 1 | 2010 | 502 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2006 | 78 | 0.020 |
Why?
| | Granzymes | 1 | 2006 | 40 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2006 | 124 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 154 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2006 | 156 | 0.020 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 15 | 0.020 |
Why?
| | Family | 1 | 2009 | 587 | 0.020 |
Why?
| | CA-125 Antigen | 1 | 2005 | 14 | 0.020 |
Why?
| | Homeostasis | 1 | 2009 | 594 | 0.020 |
Why?
| | Inpatients | 1 | 2009 | 389 | 0.020 |
Why?
| | Exoribonucleases | 1 | 2006 | 39 | 0.020 |
Why?
| | Heme | 1 | 1985 | 54 | 0.020 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2005 | 14 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 235 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 547 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2006 | 147 | 0.020 |
Why?
| | Iodized Oil | 1 | 2005 | 1 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 105 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 968 | 0.020 |
Why?
| | Epithelium | 1 | 2006 | 305 | 0.020 |
Why?
| | Methotrexate | 1 | 2006 | 227 | 0.020 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2004 | 16 | 0.020 |
Why?
| | bcl-X Protein | 1 | 2004 | 41 | 0.020 |
Why?
| | Janus Kinase 2 | 1 | 2004 | 32 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 1323 | 0.020 |
Why?
| | Bile | 1 | 2004 | 31 | 0.020 |
Why?
| | Biliary Tract Diseases | 1 | 2004 | 35 | 0.020 |
Why?
| | Caspases | 1 | 2006 | 269 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 1987 | 477 | 0.020 |
Why?
| | Histocytological Preparation Techniques | 1 | 2004 | 2 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 965 | 0.020 |
Why?
| | DNA | 1 | 2011 | 1388 | 0.020 |
Why?
| | Paraffin Embedding | 1 | 2004 | 22 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 55 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 2073 | 0.020 |
Why?
| | Methyl n-Butyl Ketone | 1 | 1983 | 1 | 0.020 |
Why?
| | Chloroform | 1 | 1983 | 4 | 0.020 |
Why?
| | Blotting, Western | 1 | 2007 | 1195 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2005 | 113 | 0.020 |
Why?
| | Research Design | 1 | 2010 | 969 | 0.020 |
Why?
| | Phenobarbital | 1 | 1983 | 18 | 0.020 |
Why?
| | Chile | 1 | 2003 | 16 | 0.010 |
Why?
| | Ketones | 1 | 1983 | 45 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 226 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1136 | 0.010 |
Why?
| | Rats | 6 | 1988 | 5394 | 0.010 |
Why?
| | Child, Preschool | 2 | 2009 | 9493 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2003 | 311 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 2092 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2009 | 993 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 770 | 0.010 |
Why?
| | Rats, Inbred Strains | 3 | 1985 | 394 | 0.010 |
Why?
| | Physicians | 1 | 2009 | 794 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2000 | 41 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1802 | 0.010 |
Why?
| | Phylogeny | 1 | 2003 | 817 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 726 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 4552 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 5256 | 0.010 |
Why?
| | Image Enhancement | 1 | 2000 | 181 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1997 | 46 | 0.010 |
Why?
| | Antimetabolites | 1 | 1997 | 25 | 0.010 |
Why?
| | Drug Interactions | 1 | 1997 | 352 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1997 | 415 | 0.010 |
Why?
| | Infant | 1 | 2009 | 8295 | 0.010 |
Why?
| | Lymphogranuloma Venereum | 1 | 1951 | 2 | 0.010 |
Why?
| | Neck | 1 | 1951 | 89 | 0.010 |
Why?
| | Phenylisopropyladenosine | 1 | 1987 | 5 | 0.010 |
Why?
| | Chemistry | 1 | 1987 | 39 | 0.000 |
Why?
| | Chemical Phenomena | 1 | 1987 | 82 | 0.000 |
Why?
| | Diglycerides | 1 | 1987 | 56 | 0.000 |
Why?
| | Phosphatidylethanolamines | 1 | 1987 | 66 | 0.000 |
Why?
| | Aniline Compounds | 1 | 1987 | 71 | 0.000 |
Why?
| | Prodrugs | 1 | 1987 | 44 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1988 | 522 | 0.000 |
Why?
| | Electrophoresis | 1 | 1985 | 26 | 0.000 |
Why?
| | Acetylation | 1 | 1985 | 217 | 0.000 |
Why?
| | Fatty Acids | 1 | 1987 | 407 | 0.000 |
Why?
| | Cerebral Cortex | 1 | 1987 | 416 | 0.000 |
Why?
| | Benzphetamine | 1 | 1983 | 1 | 0.000 |
Why?
| | Chromatography, Ion Exchange | 1 | 1983 | 51 | 0.000 |
Why?
| | Cell Membrane | 1 | 1987 | 710 | 0.000 |
Why?
| | Oxidation-Reduction | 1 | 1984 | 940 | 0.000 |
Why?
| | Oxygen | 1 | 1984 | 857 | 0.000 |
Why?
|
|
Schulick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|